AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06130878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic exercise
Description: A multicomponent rhythmic physical training will be carried out, with a predominance of QMT, following the principles of Animal Flow \[46\] and including the following components: wrist mobilizations; activations; specific stretching positions; special locomotor movements or traveling forms; interruptions and transitions with dynamic movements and choreographic sequences of Flow. Aspects related to the control of intensity, volume and progression strategy have yet to be defined.
Study NCT06443320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: videodrama sessions
Description: Patients will benefit from videodrama sessions, one per week for 9 sessions
Study NCT05553613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 MG Oral Tablet
Description: Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study NCT05927142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Human anti-PD-L1 antibody
Study NCT05927142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rintatolimod
Description: TLR-3 agonist, synthetic double-stranded ribonucleic acid (poly I:C12U)
Study NCT06185972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: Stimulation of Definity microbubbles using Sonalleve device within tumour vasculature
Study NCT06185972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonalleve Focused Ultrasound Device
Description: Sonalleve Focused Ultrasound Device
Study NCT04306848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporary Continuous Glucose Monitoring System
Description: This is a feasibility study evaluating the potential to utilize a continuous glucose monitoring system (CGMs) on a temporary basis, during participation in an intensive therapeutic lifestyle medicine program, to help improve the compliance with healthy lifestyle changes for people with Type 2 diabetes (T2DM) and prediabetes (PD).
Study NCT05964387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDF
Description: 38% SDF will be applied to the hypoplastic area of the enrolled first permanent molar.
Study NCT05964387 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inert liquid will be applied to the hypoplastic area of the enrolled first permanent molar.
Study NCT05039073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study NCT05039073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HSCT
Study NCT05039073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT05039073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05039073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06362226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid/Antibiotic (Maxitrol)
Description: Group one subjects receive topical maxitrol ophthalmic ointment twice daily for two weeks
Study NCT06362226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU/Kenalog
Description: Group two undergoes treatment with a subcutaneous injection of a 5-fluorouracil (5-FU) and Kenalog (triamcinolone) combination (80/20 ratio, 0.3-0.5 mL per session) administered in four sessions, spaced two weeks apart, starting within 48 hours of hospital presentation
Study NCT04969471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enVast stent
Description: In addition to conventional treatment, the treating physician will deploy as the first measure to obtain reperfusion, a enVast stent at the occlusion site in order to withdraw the clot.
Study NCT04969471 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: Treatment strategies may include balloon angioplasty, manual aspiration thrombectomy and/or coronary stenting.
Study NCT05627362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor 80 mg
Description: Oral Tablet
Study NCT05627362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor 120 mg
Description: Oral Tablet
Study NCT05627362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matched to Elafibranor 80 mg
Description: Oral Tablet
Study NCT05627362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Matched to Elafibranor 80 mg
Description: Oral Tablet
Study NCT05627362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matched to Elafibranor 120 mg
Description: Oral Tablet
Study NCT04850820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Novel essential amino acid supplementation
Description: This intervention will determine the impact of EAA+ on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
Study NCT04850820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Branched-chain amino acid supplementation (BCAA)
Description: This intervention will determine the impact of the BCAA supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
Study NCT04850820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric carbohydrate supplementation
Description: This intervention will determine the impact of an isocaloric carbohydrate placebo supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
Study NCT04850820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Isocaloric carbohydrate supplementation
Description: This intervention will determine the impact of an isocaloric carbohydrate placebo supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
Study NCT04247022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health care product (intimate gel)
Description: heath care product (intimate gel) for home use, under real conditions of use, for 28 ± 2 days
Study NCT05808166 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hecolin® (Recombinant Hepatitis E Vaccine (Escherichia coli)).
Description: Hecolin® will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 1), and 0, 1 and 6 months for the non-pregnant participant (arm 3).
Study NCT05808166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hecolin® (Recombinant Hepatitis E Vaccine (Escherichia coli)).
Description: Hecolin® will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 1), and 0, 1 and 6 months for the non-pregnant participant (arm 3).
Study NCT05808166 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Sodium Chloride injection
Description: Placebo will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 2)
Study NCT06535035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser therapy After implant surgery, laser therapy (LLLT) was applied
Description: After implant surgery, laser therapy (LLLT) was applied a single session with an EPIC X Biolase diode laser (BIOLASE, Inc., USA)
Study NCT06535035 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: After implant surgery, After implant surgery, laser therapy (LLLT) was applied in the same manner but without activating it
Study NCT05886257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candonilimab
Description: 10mg/kg, iv.drip, every 3 week
Study NCT05886257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg, iv.drip, every 3 week
Study NCT04851457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous tirofiban combination therapy
Description: Patients will enter the tirofiban treatment protocol immediately within half an hour after randomization and prior to the femoral artery puncture. Tirofiban is administered as an intravenous bolus dose of 10 μg/kg injection within 3 min and then by an intravenous infusion at a rate of 0.1 μg/(kg·min) for 24 hours.
Study NCT05310448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune device
Description: Wear Optune device
Study NCT05101785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocain hydrochloride 2 % with epinephrine
Description: Local anesthesia infilteration in children
Study NCT05101785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine chloride 4% with epinephrine
Description: Articaine chloride 4% with epinephrine
Study NCT05340075 — intervention group
Intervention type: PROCEDURE
Intervention: Patients who underwent percutaneous nephrolithotomy
Description: Patients who underwent percutaneous nephrolithotomy to the contralateral kidney 2-4 weeks and 4-6 weeks after the percutaneous nephrolithotomy operation
Study NCT05832801 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ( Traditional dietary advice )
Description: traditional dietary advice for IBS which is based on guidance provided by the National Institute for Health and Care Excellence (NICE ) and the British Dietetic Association (BDA). Its principles include adopting healthy, sensible eating patterns such as having regular meals, never eating too little/too much, maintaining adequate hydration, and reducing the intake of (1) alcohol/caffeine/fizzy drinks, (2) fatty/spicy/processed foods, (3) fresh fruit to a maximum of 3 per day, (4) fiber and other commonly consumed gas-producing foods (eg, beans, bread, sweeteners, etc), and (5) addressing any perceived food intolerances (eg, dairy).
Study NCT05832801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ( Traditional dietary advice )
Description: traditional dietary advice for IBS which is based on guidance provided by the National Institute for Health and Care Excellence (NICE ) and the British Dietetic Association (BDA). Its principles include adopting healthy, sensible eating patterns such as having regular meals, never eating too little/too much, maintaining adequate hydration, and reducing the intake of (1) alcohol/caffeine/fizzy drinks, (2) fatty/spicy/processed foods, (3) fresh fruit to a maximum of 3 per day, (4) fiber and other commonly consumed gas-producing foods (eg, beans, bread, sweeteners, etc), and (5) addressing any perceived food intolerances (eg, dairy).
Study NCT05832801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (Pilates exercises)
Description: Pilates exercises will be in the form of Swan, One leg up-down, Leg circles, Single leg stretch, Saw, Side kicks, The hundred,. Pelvic lift on the ball, Sit-ups with the ball, Stretching on the ball. exercise Dose will be First month (first- eighth session) composed of one set of eight repetitions Second month (eighth-sixteenth session) composed of two sets of ten repetitions
Study NCT05397886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Besylate
Description: Remimazolam Besylate is used as intervention drug for general anesthesia, which followed by flumazenil administration at the end of anesthesia, to be compared to propofol total intravenous anesthesia during radiofrequency catheter ablation of atrial fibrillation.
Study NCT05397886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: Flumazenil is used as additional intervention drug to facilitate emergence from general anesthesia in the Remimazolam with Flumazenil group.
Study NCT05397886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is used as active comparator drug for general anesthesia until the end of anesthesia, to be compared to remimazolam besylate during radiofrequency catheter ablation of atrial fibrillation.
Study NCT05790811 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician-oriented Video
Description: previously validated Hand and Wrist Examination Video by NEJM designed for usage by a physician in diagnosing common hand and wrist diagnoses
Study NCT05790811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-oriented video
Description: The previously validated Hand and Wrist Examination Video by NEJM was modified via the TogoTiki application and approved by a patient advisory council.
Study NCT05284578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-compassionate writing intervention
Description: Participants assigned to this intervention were asked to engage in one brief online self-compassionate writing session, where they were asked to write about and experience their feelings from the perspective of an inner compassionate observer.
Study NCT05284578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expressive writing intervention
Description: Participants assigned to this intervention were asked to engage in one brief online expressive writing session, where they were asked to explore their deepest thoughts and emotions surrounding an upsetting situation through writing.
Study NCT05284578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control writing task
Description: Participants assigned to this condition were asked to engage in a neutral time management writing task.
Study NCT06002113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GOCD Tool
Description: Web-based tool with 4 components; pre-admission health status; current illness prognosis for hospital survival; in-hospital cardiorespiratory arrest prognosis; values and goals of care
Study NCT06002113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Attending physicians responsible for GOCD during hospitalization using their usual approaches
Study NCT06193928 — intervention group
Intervention type: DRUG
Intervention: Maralixibat
Description: The recommended dosage is 380 mcg/kg once daily.
Study NCT05825469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Algorithm
Description: A technology-based platform for a person-centered nutrition program, providing suggested foods and recipes from dietitians.
Study NCT05438329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1305/BNT325
Description: Administered Injection of Vein (I.V.)
Study NCT06175455 — intervention group
Intervention type: DEVICE
Intervention: dynamic chest radiography
Description: A recent technological advancement in this field is dynamic chest radiography (DCR), which is a low-dose imaging system capable of producing continuous moving images
Study NCT05864755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC+Durvalumab+Tremelimumab+Bevacizumab
Description: Tremelimumab：300mg, only once in cycle 1.Durvalumab: 1500mg, iv,q3w Bevacizumab: 15mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin
Study NCT06134752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulse field ablation
Description: Point by point isolation of pulmonary veins and left atrial posterior wall
Study NCT06134752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Point by point isolation of pulmonary veins and left atrial posterior wall
Study NCT05759078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject
Description: The first dose of FCM will be administered during the first visit on the day of randomisation (V1). Then, the participants will be reassessed at 4 and 8 months (visits V2, V3) for: haemoglobin, serum ferritin and TSAT. They will receive an additional dose of 1000 mg of FCM during these visits if ferritin \<100 ng/mL or/and TSAT \<20% (ferritin cannot exceed 400 ng/dL, TSAT cannot exceed 40%, haemoglobin cannot exceed 15 g/dL). If these criteria are not fulfilled, a patient in the active study arm will receive i.v. NaCl 0.9% during the particular visit.
Study NCT05759078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: The first dose of placebo will be administered during the first visit on the day of randomisation (V1). During visits V2 i V3 (at 4 and 8 months) they will receive next dose of placebo.
Study NCT04239859 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: secukinumab
Description: Secukinumab for 6 months, given at weeks 0, 1, 2, 3 and 4, then monthly till 6 months. 300mg per administration, subcutaneously.
Study NCT04239859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Oral tablet up to 15mg per week
Study NCT04239859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A
Description: Oral capsule up to 200mg per day
Study NCT04239859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin
Description: Oral capsule up to 25mg per day
Study NCT05235451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human-Animal Interactions
Description: Human-animal interactions (HAI) is a powerful and cost-effective strategy to improve reading fluencies and comprehension of children with learning differences. Emerging data suggest that HAI help promote classroom behaviors and learning, including effects on cognition, emotional functioning, and motor skills for children with and without learning differences. The HAI reading group will receive reading instruction as usual plus visits from a registered therapy dog team (dog + animal handler) twice a week over 12 weeks.
Study NCT05945628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Different cognitive and memory demands during the memory experiment
Description: Study conditions will involve attempting to memorize visual scenes, attempting to memorize arrays of visual objects, viewing in a self-directed manner, viewing in a passive other-directed manner, and making memory judgments about whether stimuli are studied versus novel.
Study NCT05945628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different electrical stimulation parameters during cognitive and memory demands
Description: Study conditions will involve different parameters for electrical stimulation delivered through iEEG electrodes, including the presence of stimulation (no stimulation versus stimulation) and the location of stimulation (hippocampus versus amygdala).
Study NCT05438329 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered I.V.
Study NCT05438329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327
Description: Administered I.V.
Study NCT06180720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)
Description: Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.
Study NCT06180720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)
Description: Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
Study NCT04763785 — intervention group
Intervention type: DEVICE
Intervention: Corneal tomography with Eyestar 900
Description: Non-invasive corneal tomography to develop an imaging analysis algorithm for keratoconus corneas
Study NCT04763785 — intervention group
Intervention type: DEVICE
Intervention: Corneal tomography with Pentacam
Description: Non-invasive corneal tomography to develop an imaging analysis algorithm for keratoconus corneas
Study NCT04763785 — intervention group
Intervention type: DEVICE
Intervention: Biometry with IOL-Master
Description: Non-invasive biometry for presurgical intraocular lens calculation
Study NCT04763785 — intervention group
Intervention type: OTHER
Intervention: retrospective analysis, no intervention
Description: retrospective analysis of 4500 existing, fully anonymised picture data
Study NCT04636073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leaflex™ Performer
Description: A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
Study NCT04123704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: sitravatinib capsule
Study NCT05841667 — intervention group
Intervention type: DRUG
Intervention: Remimazolam besylate
Description: This is an observational study, meaning that no interventions are actually administered to the participants. However, blood and urine samples will be collected for research purposes.~Participants will receive remimazolam besylate for at least 2 hours during anesthesia and surgery. Blood will be drawn to determine the concentration of remimazolam in the blood at the following time points: (1) before remimazolam administration, (2) after remimazolam administration has lasted at least 2 hours without a change in concentration, (3) immediately before discontinuation of remimazolam if there has been a change in concentration since the second blood draw, (4) within 5 minutes of discontinuation, (5) within 15-60 minutes of discontinuation, and (6) 90 minutes after discontinuation. Urine will also be collected after the end of anesthesia to check for metabolites of remimazolam.